Proficio Capital Partners’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Proficio Capital Partners’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-178	Closed	-$1K	–	1690
2019 Q2	$1K	Buy	178 +119	+202%	+$566	﹤0.01%	1857
2019 Q1	$0	Buy	+59	New	+$381	﹤0.01%	1794

Other funds holding PRTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Proficio Capital Partners's PRTK Position: Q3 2019 in Review

Proficio Capital Partners sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2019, closing a stake of 178 shares — an estimated $1K sold.

Proficio Capital Partners first reported a position in PRTK in Q1 2019 and held it in 2 quarters. The position peaked at $1K in Q2 2019. 91 funds tracked by Wall St. Rank hold PRTK as of Q3 2019.

Proficio Capital Partners reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
Proficio Capital Partners sold 178 Paratek Pharmaceuticals, Inc. shares in Q3 2019, an estimated $1K.
Proficio Capital Partners first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2019 and held it in 2 quarters.
Proficio Capital Partners's Paratek Pharmaceuticals, Inc. position peaked at $1K in Q2 2019.
91 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2019.

Based on Proficio Capital Partners's 13F filing for Q3 2019, filed 13 Nov 2019.